14 companies were scheduled to go public this week, including 10 health care deals. Only 8 IPOs got through, as 3 biotechs have been pushed back to next week, two companies postponed and one withdrew. however; IPO investors had plenty of options while the NASDAQ...read more
Adaptimmune Therapeutics, which is developing cancer immunotherapies using genetically enhanced T-cell receptors, raised $191 million by offering 11.3 million shares at $17, at high end of the $15-$17 range. At its offer price, Adaptimmune Therapeutics will...read more
This could be the busiest 5-day stretch in the IPO market since the week of July 28, 2014, as 14 companies look to raise nearly $2 billion. However, ...read more
Adaptimmune Therapeutics, which is developing cancer immunotherapies based on genetically engineered T-cell receptors, announced terms for its IPO on Monday. The Abingdon, United Kingdom-based company plans to raise $150 million by offering 9.4 million shares at...read more
US IPO Weekly Recap: With 8 IPOs it's Bo-Time for Bojangles and no time for biotechs
14 companies were scheduled to go public this week, including 10 health care deals. Only 8 IPOs got through, as 3 biotechs have been pushed back to next week, two companies postponed and one withdrew. however; IPO investors had plenty of options while the NASDAQ...read more
Adaptimmune Therapeutics prices upsized IPO at $17, the high end of the range
Adaptimmune Therapeutics, which is developing cancer immunotherapies using genetically enhanced T-cell receptors, raised $191 million by offering 11.3 million shares at $17, at high end of the $15-$17 range. At its offer price, Adaptimmune Therapeutics will...read more
Week ahead: 14 IPOs planned for the week of May 4
This could be the busiest 5-day stretch in the IPO market since the week of July 28, 2014, as 14 companies look to raise nearly $2 billion. However, ...read more
Cancer immunotherapy biotech Adaptimmune Therapeutics sets terms for $150 million IPO
Adaptimmune Therapeutics, which is developing cancer immunotherapies based on genetically engineered T-cell receptors, announced terms for its IPO on Monday. The Abingdon, United Kingdom-based company plans to raise $150 million by offering 9.4 million shares at...read more